TEACHER
- Organizing Committee Members
- International Committee
- 2025 Company Presentations
- Plenary Session 1 – Global Biotech Development
- Plenary Session 2 – Global Biotech Development
- Plenary Session 3 – The Value of Innovation for a Healthier Taiw
- Session A-1 – New Therapeutic Modalities
- Session A-2 – Gene and Cell Therapies- Advanced Manufacture and
- Session A-3 – AI & Translational Medicine
- Session A-4 – Taiwan BIO Awards-Successful Stories
- Session A-5 – Decision Making on Outsourcing in the Current Chan
- Session A-6 – Innovative Developments and Cross-Disciplinary App
- Session A-7 – Innovative Developments and Cross-Disciplinary App
- Session A-8 – Novel ADC-based Target Therapy
- Session A-9 – Smart HealthCare
- Session A-10 – Exploring the Future of Precision Health in Taiw
- Session A-11 – Special Session: Digital Health
- Session A-12 – Alzheimer’s Disease Forum
- Investment Summit Session B - 1
- Investment Summit Session B - 2
- Regional Collaboration Forum-Thailand
- Regional Collaboration Forum-Malaysia
- Satellite Symposia
- Regional Collaboration Forum-Canada
- Regional Collaboration Forum-Japan
- Regional Collaboration Forum-U.S.A
Yuji Habara
Plenary Session 3 – The Value of Innovation for a Healthier Taiwan
Date：23 July
Time：12:05 - 12:20, 13:05 - 13:17 (GMT+8)
Yuji Habara
President & General Manager
Chugai Pharma Taiwan
He joined Chugai in 2002 and beginning his career in the Production Division until 2009, he specialized in raw material procurement and active pharmaceutical ingredient manufacturing for antibody drugs, gaining invaluable experience with regulatory inspections from FDA, EMA, PMDA, and other international authorities for manufacturing and marketing authorization.
Over twelve years, he experienced to market access for pharmaceuticals and medical devices, developing deep expertise in product pricing and reimbursement strategies, insurance coverage applications, and government advocacy through industry activities. This role provided critical insights into healthcare policy, market dynamics across multiple therapeutic areas and value co-creation as patient advocacy for innovative therapeutics.
Most notably, he served as Product Lifecycle Leader for multiple breast cancer therapeutics in various product lifecycle stages, orchestrating comprehensive product management from early-stage through late-stage development and post-launch activities. This role encompassed non-clinical & clinical, regulatory affairs, medical affairs, marketing, intellectual property, pricing and reimbursement, market distribution, and business development—demonstrating exceptional ability to integrate cross-functional expertise for successful product commercialization.
Speech title & Synopsis
Pioneering Healthcare Innovation: Chugai's Technology-Driven Approach to Drug Discovery
Chugai Pharmaceutical, Japan's leading drug discovery company will present its innovative approach to addressing unmet medical needs through proprietary technology platforms.
Since establishing its strategic alliance with Roche in 2002, Chugai has achieved remarkable growth with revenue increasing and operating profit growing. The company's success stems from its technology-driven drug discovery strategy, creating breakthrough therapeutics including an-IL-6 receptor antibody for rheumatoid arthritis, a small molecule anti-ALK fusion protein inhibitor for lung cancer, and a bispecific antibody for hemophilia A and others.
This presentation will showcase Chugai's unique proprietary technologies that differentiate the company in the global pharmaceutical landscape. Key innovations include three revolutionary antibody engineering platforms: Recycling Antibodies that bind antigens multiple times for enhanced efficacy with reduced dosing; Sweeping Antibodies that rapidly remove target antigens from plasma; and Switch Antibodies that selectively bind antigens in specific microenvironments to address toxicity challenges.
Additionally, Chugai's mid-size molecule technology targets "undruggable" proteins that conventional antibodies and small molecules cannot address. These orally available cyclic peptides can enter cells and interfere with protein-protein interactions at picomolar levels, expanding therapeutic possibilities beyond traditional modalities.
Unlike competitors focused on specific disease areas, Chugai applies its technology platforms across multiple therapeutic areas with unmet medical needs in the multiple disease area. Chugai actively seeks strategic collaborations and has established a venture fund to invest in innovative startups.
This session will demonstrate how Chugai's technology-driven approach creates sustainable competitive advantages and delivers transformative medicines for patients worldwide.
